Furthermore, other studies showed that the IL-33/ST2 axis increased effector T-cell responses to worsen acute GVHD [32], and ST2 blockade reduced GVHD severity and mortality while preserving graft-versus-leukemia activity [33]. Here, IL1RL1 is linked to graft versus host disease.